A Study to Evaluate the Activity, Safety and Tolerability of ZX-101A in Advanced Solid Tumors

Summary

ZX-101A-201 is a phase I, open-label, multicenter study which includes dose escalation and dose expansion of ZX-101A. It is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and antitumor activity of ZX-101A in patients with advanced solid tumors.

Timeline

Start

2022-03-09

Primary completion

2023-06-30

Completion

2024-04-30

Drugs

Indications